Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
555 studies found for:    NR3C2
Show Display Options
Rank Status Study
1 Recruiting Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size
Condition: ST-elevation Myocardial Infarction
Interventions: Drug: Mineralocorticoid receptor antagonist potassium-canrenoate;   Drug: placebo
2 Enrolling by invitation Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology
Condition: Kidney Failure, Chronic
Intervention: Drug: spironolactone
3 Completed Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Conditions: Obesity;   Insulin Resistance
Interventions: Drug: Spironolactone;   Drug: Placebo
4 Completed Mineralocorticoid Receptor in the Treatment of Severe Depression
Condition: Major Depression
Interventions: Drug: Spironolactone;   Drug: fludrocortisone;   Drug: escitalopram
5 Recruiting Hypoglycemia and the Mineralocorticoid Receptor
Condition: Hypoglycemia
Intervention: Drug: Eplerenone
6 Completed Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
Conditions: Type 2 Diabetes Mellitus;   Vascular Disease
Interventions: Drug: Spironolactone;   Drug: hydrochlorothiazide + potassium;   Other: placebo
7 Completed Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study
Condition: Heart Failure
Intervention: Drug: Canrenone
8 Not yet recruiting Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis (MIRACULOUS) Trial
Condition: Atherosclerosis
Intervention: Drug: Eplerenone
9 Completed The Role of Mineralocorticoid Receptors in Vascular Function
Condition: Apparent Mineralocorticoid Excess (AME)
Interventions: Drug: Glycyrrhetic Acid;   Drug: Placebo
10 Completed Cardiovascular Evaluation of Adult PHA 1 Patients
Condition: Pseudohypoaldosteronism Type 1
11 Recruiting Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
Condition: End Stage Renal Disease / Hemodialysis
Intervention: Drug: Spironolactone
12 Completed Eplerenone and Extracellular Adenosine Formation
Condition: Pharmacodynamics
Interventions: Drug: Eplerenone;   Drug: Placebo
13 Unknown  Aldosterone and the Metabolic Syndrome
Conditions: Metabolic Diseases;   Diabetes Mellitus;   Endocrine System Diseases;   Glucose Metabolism Disorders
Interventions: Drug: Renin-Angiotensin-Aldosterone System (RAAS) Activation;   Drug: Administration of Aliskiren, Spironolactone, or Placebo;   Drug: Increased Dose, Combination, or Placebo
14 Completed Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human
Condition: Cardiovascular Diseases
Interventions: Procedure: Urinary and blood lipococalin levels determination;   Drug: Spironolactone
15 Completed
Has Results
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Conditions: Systemic Arterial Hypertension;   Hypertension Resistant to Conventional Therapy;   Myocardial Infarction;   Stroke
Intervention: Drug: Anti-hypertensive drug treatment
16 Not yet recruiting Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment
Conditions: Primary Aldosteronism;   Primary Hyperaldosteronism
17 Completed Fludrocortisone and Information Processing in Healthy Volunteers
Condition: Depression
Interventions: Drug: Fludrocortisone;   Drug: Placebo
18 Completed
Has Results
Patient's Management Receiving Eplerenone Therapy
Condition: Left Ventricular Dysfunction Post Myocardial Infarction
Intervention: Other: Prospective Observational
19 Terminated Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function
Condition: Chronic Kidney Disease
Intervention: Drug: Eplerenone
20 Completed Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System
Conditions: Chronic Kidney Disease;   Proteinuria
Intervention: Drug: Spironolactone (Spironol) 25 mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years